When newborn babies suffer from respiratory failure, inhaling nitric oxide can help them breathe easier. Third Pole Therapeutics Founder Dr. Warren Zapol invented the treatment, and over the next two decades, built it into a scalable technology that has benefited hundreds of thousands of pediatric and adult patients alike.
The company is at the leading edge of a $600 million inhaled nitric oxide market, as its technology solves the cost and logistical hurdles of systems that use compressed gas cylinders.
Third Pole Therapeutics’ two novel platforms include eNOfit™, a miniaturized wearable device for home and travel, and eNOcare™, a lightweight portable in-hospital device. Both generate inhaled nitric oxide by combining electricity and the air we breathe, creating a “make it and take it” therapy, free from the hazards of compressed gas storage.
These broadly patented, versatile platforms have the potential to expand to treat interstitial lung disease (ILD), chronic obstructive pulmonary disease (COPD) and cystic fibrosis, as well as life-threatening viral and bacterial infections.
BioSpace – Third Pole Therapeutics Closes $25M Financing — eNOfit Wearable Device Now Ready for Clinical Trials
Bloomberg – This Milk-Jug-Size Device Can Help Newborns Breathe
Medgadget – Third Pole’s On-Demand Portable iNO: Interview with Dr. Warren Zapol
Medical Device Network – Third Pole Concludes Nitric Oxide Trial
Medical Device Network – Third Pole Doses First Patient in Trial with Nitric Oxide Delivery System
National Heart, Lung, and Blood Institute – Treating Pulmonary Hypertension: New Delivery System to Change How Babies Receive Nitric Oxide Therapy
Pulmonary Hypertension News – Early Study of Inhaled Nitric Oxide Delivery System Doses 1st Patient
Pulmonary Hypertension News – Third Pole’s Lighter Nitric Oxide System Wins Johnson & Johnson Innovation Award
Pulmonary Hypertension News – Third Pole’s Portable Inhaled Nitric Oxide Device Clears Early Study
National Institutes of Health Small Business Innovation Research Awards – 2021 Phase II Award, 2019 Phase II Award and two 2016 Phase II Awards
Johnson & Johnson Innovation – JLABS @ M2D2 QuickFire Challenge Awardee
Every year, American entrepreneurs start more than half a million companies. More than 90% of them will fail, with only 200 ever passing $100 million in revenue. At Unorthodox Ventures, we know how to reach $300 million. Jump in with us.
